Okay—thanks. Still, the 80% "PoS" figure was ludicrous in its own right, given that the Daxxify sBLA for CD had no new formulation or manufacturing requirements and Daxxify's clinical dataset in CD was superb.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”